Brief: Checkpoint Therapeutics Strengthens Intellectual Property Protection For Cosibelimab With New U.S. Patent Issuance
05/12/2023 13:35
Dec 5 (Reuters) - Checkpoint Therapeutics Inc CKPT.O :
* CHECKPOINT THERAPEUTICS STRENGTHENS INTELLECTUAL PROPERTY
PROTECTION FOR COSIBELIMAB WITH NEW U.S. PATENT ISSUANCE
* CHECKPOINT THERAPEUTICS INC - U.S. PATENT PROTECTION FOR
COSIBELIMAB THROUGH AT LEAST MAY 2038
* CHECKPOINT THERAPEUTICS INC - UPCOMING PDUFA GOAL DATE OF
JANUARY 3, 2024
Source text for Eikon: ID:nGNX2BH4Tp
Further company coverage: CKPT.O
((Reuters.Briefs@thomsonreuters.com;))
Recent news on Fortress Biotech
See all newsFortress Biotech Inc reports results for the quarter ended June 30 - Earnings Summary
Fortress Biotech Inc expected to post a loss of 20 cents a share - Earnings Preview
Brief: Fortress Biotech And Subsidiary Urica Therapeutics Announce Crystalys Therapeutics’ $130 Million Series B Financing
Fortress Biotech Q1 net income jumps on PRV sale
Brief: Journey Medical Corporation Secures Contract With Third Major Gpo For Emrosi